Does the media prefer HALO or NRIX?

In the previous week, Halozyme Therapeutics had 11 more articles in the media than Nurix Therapeutics. MarketBeat recorded 15 mentions for Halozyme Therapeutics and 4 mentions for Nurix Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.04 beat Nurix Therapeutics' score of 0.97 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NRIX or SMMT?

In the previous week, Summit Therapeutics had 5 more articles in the media than Nurix Therapeutics. MarketBeat recorded 9 mentions for Summit Therapeutics and 4 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.97 beat Summit Therapeutics' score of 0.37 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NRIX or PRAX?

In the previous week, Nurix Therapeutics and Nurix Therapeutics both had 4 articles in the media. Nurix Therapeutics' average media sentiment score of 0.97 beat Praxis Precision Medicines' score of 0.62 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NRIX or ABVX more profitable?

Abivax has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Nurix Therapeutics' return on equity of -76.09% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Nurix Therapeutics -928.44% -76.09% -57.31% Abivax N/A -99.02% -70.26%

Does the media favor NRIX or ABVX?

In the previous week, Nurix Therapeutics had 3 more articles in the media than Abivax. MarketBeat recorded 4 mentions for Nurix Therapeutics and 1 mentions for Abivax. Abivax's average media sentiment score of 1.76 beat Nurix Therapeutics' score of 0.97 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to KYMR or NRIX?

In the previous week, Kymera Therapeutics had 5 more articles in the media than Nurix Therapeutics. MarketBeat recorded 9 mentions for Kymera Therapeutics and 4 mentions for Nurix Therapeutics. Kymera Therapeutics' average media sentiment score of 1.24 beat Nurix Therapeutics' score of 0.97 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nurix Therapeutics (NRIX) Competitors

$26.72 -0.33 (-1.22%)

As of 08/21/2026 04:00 PM Eastern

Compare

NRIX vs. HALO, SMMT, PRAX, ABVX, and KYMR

Should you buy Nurix Therapeutics stock or one of its competitors? Nurix Therapeutics's main competitors and comparable companies include Halozyme Therapeutics (HALO), Summit Therapeutics (SMMT), Praxis Precision Medicines (PRAX), Abivax (ABVX), and Kymera Therapeutics (KYMR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nurix Therapeutics compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Nurix Therapeutics (NASDAQ:NRIX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

Halozyme Therapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

Halozyme Therapeutics has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.66B	7.38	$316.89M	$3.35	32.29
Nurix Therapeutics	$83.98M	33.02	-$264.46M	-$3.45	N/A

Halozyme Therapeutics has a net margin of 24.86% compared to Nurix Therapeutics' net margin of -928.44%. Halozyme Therapeutics' return on equity of 260.98% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

Halozyme Therapeutics currently has a consensus price target of $91.20, suggesting a potential downside of 15.69%. Nurix Therapeutics has a consensus price target of $34.21, suggesting a potential upside of 28.05%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

97.8% of Halozyme Therapeutics shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Halozyme Therapeutics had 11 more articles in the media than Nurix Therapeutics. MarketBeat recorded 15 mentions for Halozyme Therapeutics and 4 mentions for Nurix Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.04 beat Nurix Therapeutics' score of 0.97 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nurix Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Halozyme Therapeutics beats Nurix Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Nurix Therapeutics compare to Summit Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Nurix Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.23, suggesting that its stock price is 223% less volatile than the broader market.

Summit Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Nurix Therapeutics' return on equity of -76.09% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Summit Therapeutics	N/A	-168.94%	-141.92%

In the previous week, Summit Therapeutics had 5 more articles in the media than Nurix Therapeutics. MarketBeat recorded 9 mentions for Summit Therapeutics and 4 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.97 beat Summit Therapeutics' score of 0.37 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

4.6% of Summit Therapeutics shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Nurix Therapeutics presently has a consensus target price of $34.21, suggesting a potential upside of 28.05%. Summit Therapeutics has a consensus target price of $24.25, suggesting a potential upside of 84.24%. Given Summit Therapeutics' higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Summit Therapeutics	2 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.38

Nurix Therapeutics has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	33.02	-$264.46M	-$3.45	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Summary

Nurix Therapeutics beats Summit Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Nurix Therapeutics compare to Praxis Precision Medicines?

Nurix Therapeutics (NASDAQ:NRIX) and Praxis Precision Medicines (NASDAQ:PRAX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

In the previous week, Nurix Therapeutics and Nurix Therapeutics both had 4 articles in the media. Nurix Therapeutics' average media sentiment score of 0.97 beat Praxis Precision Medicines' score of 0.62 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nurix Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	33.02	-$264.46M	-$3.45	N/A
Praxis Precision Medicines	$8.55M	1,227.30	-$303.27M	-$12.93	N/A

Nurix Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.78, meaning that its stock price is 178% more volatile than the broader market.

67.8% of Praxis Precision Medicines shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Praxis Precision Medicines has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Praxis Precision Medicines' return on equity of -34.15% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Praxis Precision Medicines	N/A	-34.15%	-32.42%

Nurix Therapeutics presently has a consensus target price of $34.21, suggesting a potential upside of 28.05%. Praxis Precision Medicines has a consensus target price of $585.95, suggesting a potential upside of 55.90%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	4 Strong Buy rating(s)	3.00

Summary

Praxis Precision Medicines beats Nurix Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Nurix Therapeutics compare to Abivax?

Nurix Therapeutics (NASDAQ:NRIX) and Abivax (NASDAQ:ABVX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Nurix Therapeutics presently has a consensus target price of $34.21, indicating a potential upside of 28.05%. Abivax has a consensus target price of $156.50, indicating a potential upside of 36.15%. Given Abivax's higher possible upside, analysts clearly believe Abivax is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

47.9% of Abivax shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Abivax has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Nurix Therapeutics' return on equity of -76.09% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Abivax	N/A	-99.02%	-70.26%

Nurix Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market. Comparatively, Abivax has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

In the previous week, Nurix Therapeutics had 3 more articles in the media than Abivax. MarketBeat recorded 4 mentions for Nurix Therapeutics and 1 mentions for Abivax. Abivax's average media sentiment score of 1.76 beat Nurix Therapeutics' score of 0.97 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Nurix Therapeutics has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	33.02	-$264.46M	-$3.45	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Summary

Nurix Therapeutics beats Abivax on 9 of the 13 factors compared between the two stocks.

How does Nurix Therapeutics compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Nurix Therapeutics (NASDAQ:NRIX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Kymera Therapeutics presently has a consensus target price of $125.65, suggesting a potential upside of 4.88%. Nurix Therapeutics has a consensus target price of $34.21, suggesting a potential upside of 28.05%. Given Nurix Therapeutics' higher possible upside, analysts plainly believe Nurix Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Kymera Therapeutics has a net margin of -285.33% compared to Nurix Therapeutics' net margin of -928.44%. Kymera Therapeutics' return on equity of -21.22% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

In the previous week, Kymera Therapeutics had 5 more articles in the media than Nurix Therapeutics. MarketBeat recorded 9 mentions for Kymera Therapeutics and 4 mentions for Nurix Therapeutics. Kymera Therapeutics' average media sentiment score of 1.24 beat Nurix Therapeutics' score of 0.97 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nurix Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kymera Therapeutics has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

Nurix Therapeutics has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	254.05	-$311.35M	-$3.24	N/A
Nurix Therapeutics	$83.98M	33.02	-$264.46M	-$3.45	N/A

Summary

Kymera Therapeutics beats Nurix Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Nurix Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRIX vs. The Competition

Export

Metric	Nurix Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.77B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-7.74	11.62	272.60	24.24
Price / Sales	33.02	1,338.17	618.96	99.81
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	5.05	16.80	13.05	6.20
Net Income	-$264.46M	-$12.50M	$3.47B	$348.59M
7 Day Performance	-1.22%	3.29%	2.09%	0.08%
1 Month Performance	12.55%	8.23%	6.64%	3.88%
1 Year Performance	163.51%	55.05%	25.02%	16.98%

Nurix Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRIX Nurix Therapeutics	2.9195 of 5 stars	$26.72 -1.2%	$34.21 +28.0%	+163.5%	$2.77B	$83.98M	N/A	300	Positive News
HALO Halozyme Therapeutics	3.8838 of 5 stars	$103.00 +4.4%	$91.20 -11.5%	+50.6%	$11.20B	$1.40B	30.75	390	Positive News Insider Trade
SMMT Summit Therapeutics	3.7989 of 5 stars	$12.78 -4.3%	$24.25 +89.7%	-49.8%	$10.65B	N/A	N/A	110	Analyst Forecast Gap Up High Trading Volume
PRAX Praxis Precision Medicines	3.0492 of 5 stars	$376.38 +2.6%	$579.55 +54.0%	+670.5%	$10.51B	N/A	N/A	110	Analyst Forecast
ABVX Abivax	2.6982 of 5 stars	$120.73 +1.5%	$156.50 +29.6%	+48.7%	$10.38B	N/A	N/A	61	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRIX) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nurix Therapeutics (NRIX) Competitors

NRIX vs. HALO, SMMT, PRAX, ABVX, and KYMR

How does Nurix Therapeutics compare to Halozyme Therapeutics?

Summary

How does Nurix Therapeutics compare to Summit Therapeutics?

Summary

How does Nurix Therapeutics compare to Praxis Precision Medicines?

Summary

How does Nurix Therapeutics compare to Abivax?

Summary

How does Nurix Therapeutics compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX vs. The Competition

Nurix Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nurix Therapeutics (NRIX) Competitors

NRIX vs. HALO, SMMT, PRAX, ABVX, and KYMR

How does Nurix Therapeutics compare to Halozyme Therapeutics?

Which has more volatility & risk, HALO or NRIX?

Which has higher earnings and valuation, HALO or NRIX?

Is HALO or NRIX more profitable?

Do analysts prefer HALO or NRIX?

Do institutionals and insiders believe in HALO or NRIX?

Does the media prefer HALO or NRIX?

Summary

How does Nurix Therapeutics compare to Summit Therapeutics?

Which has more volatility and risk, NRIX or SMMT?

Is NRIX or SMMT more profitable?

Does the media favor NRIX or SMMT?

Do insiders & institutionals have more ownership in NRIX or SMMT?

Do analysts rate NRIX or SMMT?

Which has preferable earnings and valuation, NRIX or SMMT?

Summary

How does Nurix Therapeutics compare to Praxis Precision Medicines?

Does the media favor NRIX or PRAX?

Which has better earnings & valuation, NRIX or PRAX?

Which has more volatility & risk, NRIX or PRAX?

Do insiders & institutionals believe in NRIX or PRAX?

Is NRIX or PRAX more profitable?

Do analysts prefer NRIX or PRAX?

Summary

How does Nurix Therapeutics compare to Abivax?

Do analysts prefer NRIX or ABVX?

Do insiders and institutionals believe in NRIX or ABVX?

Is NRIX or ABVX more profitable?

Which has more volatility and risk, NRIX or ABVX?

Does the media favor NRIX or ABVX?

Which has preferable valuation & earnings, NRIX or ABVX?

Summary

How does Nurix Therapeutics compare to Kymera Therapeutics?

Do analysts prefer KYMR or NRIX?

Is KYMR or NRIX more profitable?

Does the media refer more to KYMR or NRIX?

Which has more risk & volatility, KYMR or NRIX?

Which has preferable earnings & valuation, KYMR or NRIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX vs. The Competition

Nurix Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools